CXCL10 production is enhanced in the setting of HIV and HBV co-infection in vitro and decreased with the addition of antiretroviral agents efavirenz or raltegravir. by Kasha P. Singh (9354307)

Decreased BP in female mice with cardiac-specific inactivation of <i>Prdm16</i>. by Ji-One Kang (844616)

(Related to Fig 5B and 5C). Comparison of mean percentages of transfected cells with SGs calculated from three biological triplicates, showing the decrease in % as compared to wt N or the mutant N1a+N2b N. by Chiara Aloise (8374950)

Pairwise correlations in APP/PS1 mice are decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

“…(C) In vCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.138 ± 0.065, APP/PS1 = 0.112 ± 0.035, p < 10⁻⁶, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 689 units from 6 recording sessions, n_APP/PS1 = 651 units from 8 recording sessions). …”

Population entropy in APP/PS1 mice is decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

Fig 10 - by Matti Viluksela (321291)

Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1. by Udaysankar Chockanathan (18510288)

“…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10⁻⁶, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 295 units from 5 recording sessions, n_APP/PS1 = 167 units from 4 recording sessions). …”

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

Figure 5 from Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin by Joanna Domagala (21643925)

“…MFI, mean fluorescence intensity. <b>D,</b> A schematic representation of perforin maturation. …”

CcnA mutation of Loop A decreases the interaction with the 5′ UTR of P2-<i>ctrA</i> mRNA and 5′ UTR of <i>gcrA</i> mRNA. by Wanassa Beroual (5314028)

pGab1 levels decreased over time in HCV-infected Huh7.5.1 cells. by Da-eun Nam (18927946)

Algorithm operation steps. by Junyan Wang (4738518)

“…Experimental results demonstrate that SCI-YOLO11 achieves a 3.2% improvement over baseline models in terms of MAP@0.5 metric; precision and recall rates increase by 2.6% and 3.7%, respectively. …”

Silencing of TET3 acted to decrease mitochondrial respiration in N2A cells. by Valeria Leon Kropf (17797623)

eIF5a is up-regulated in unruptured AAAs and decreased in ruptured AAAs. by Dong Ma (584680)

Subjects:

HSP90 inhibition by RGRN-305 and 17-AAG decreased proinflammatory protein secretion. by Hakim Ben Abdallah (14578241)

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol. by Kaley M. Wilburn (12060476)

Percentage decreases in scores of self-reported health, large muscle function, and mobility by chronic diseases per wave after disease incidence. by James Davis (2267599)